Insitro receives $143M in series B round
The series B financing round was led by Andreessen Horowitz.
Drug discovery and development company Insitro Inc. secured $143 million in an oversubscribed series B financing round led by Andreessen Horowitz LLC.
New investors include Canada Pension Plan Investment Board; funds and accounts advised by T. Rowe Price Associates Inc.; and funds managed by BlackRock Inc., Casdin Capital LLC, HOF Capital and WuXi AppTec Sales LLC's corporate venture fund, among other undisclosed investors.
Current investors ARCH Venture Partners LLC, Foresite Capital, GV, Third Rock Ventures, Two Sigma Ventures and Alexandria Venture Investments also participated in the funding...